Search

WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ('60P' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today [...]

WASHINGTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ('60P' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, announced [...]

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine [...]

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that [...]

60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development Activity to facilitate commercial validation of new bottle and replacement blister packaging of ARAKODA[sup.(R)] [...]

WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=TtHsqdcLsUT780BOAPUn6RJuIdlW6nqA0Lw6YXi_s55qpmBZh6RNpvDuLtE4RlBZ8UikvXq5QA5kvv2oin97H1WRD_9coXOPaQfw5e5NQlCL07tvuzLkZphWlmWWmEr7jwJIdC2l74K3U827gEiiDqocZRrH9Wy3PWopTowFyc6Qci9VuWG0bkJ_e0lEFj_4ruSbWK6GFpc5rvaVQdbwMdLeTJACsYRQiRxRd8A4_SfSdrRygGgcxJHIUpNpYHrMETGr6LBnR-mvjJn2WKXz1L2JW_bnyGePuZYikSNQD3ThWUcK8PX7pGWr7xhqBNTqln-0V9G7XYR-xOr6DQ6nVnEvMiAJWUDjz_koqW8dVtJ8yHMNRmkZaWRs0NH5WofdhbfT0DdfXZzYS78F_JoR0HltjA1PGLp7oPCkjISPs4w= (NASDAQ: SXTP; SXTPW) ('60 Degrees Pharmaceuticals' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced [...]

The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted at Tufts Medical Center in Boston. Endpoints are time to [...]

The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness. The upcoming 60 Degrees Pharma clinical trial of tafenoquine in [...]

Trial planning and execution to proceed as planned WASHINGTON, May 02, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=pIhbCHg39Ma_8794vat4-m5JRtNGEuLUGJGJcWj0M6UaubvuO9Aq5NicYTRsXd2I-KWeHqFT6a1vgF4itVbF84JmE6qpsZcDdxzWoh32sTqTmlubiHqIY1hdG638W-lU (NASDAQ: https://www.globenewswire.com/Tracker?data=EWMaBZ-NVOwn7tFbBaiD0PcQM3bO7gmQXNPcpn9roW2tKXQWt5ti60XtfbfSoFHIG7tfNL5FPhDiPR5OqwxBYRp2x0UrZxAu2eDdZ5_mesA=; SXTPW) (the 'Company'), a pharmaceutical company focused on developing new medicines for [...]

Study to be conducted by North Carolina State University in 2024 Standard of care fails in 20 percent of cases and drug resistance is a problem Standard of care is [...]

WASHINGTON, March 14, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=OrN-bgGc1C1vIYR_XP0XD0n5uqDIN3DyR74jXD0H5Q2pTaV04ilCSvBO_W3pL34j13bI7utkMrYdLO8I9s_tFdUnh-SlcOGMQeKiZmptgDm-_y7RVJw0uprmiBYZR_YEMmfIQHQ-rpd5xhkCDTA8YJ9bdGjI98jgu5eSa84H8kOzKFoYwt3Pz7Vmhdp1lLJ2fC0cvzV0Tt1H4PF1NPFvHSTMYEOCxbgxOTULiQ8zwMyjr47RNCzdIgn3-0t89_ij, (NASDAQ: https://www.globenewswire.com/Tracker?data=Qi6qAktvHrdNOl_e3RG3kkojLmlVcrTXinW8RHuBj4YZZHHtJBfANdQEknYUnJwmZJwVje6JvXrKWP2xGqwkIm-mGPA5jZVR4xKNv24jBiI=, SXTPW) ('60 Degrees Pharmaceuticals' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced [...]

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals Tafenoquine 's presumed mode of action against C. auris is differentiated from standard of care treatment [...]

To lead U.S. commercial relaunch of ARAKODA(R) (tafenoquine) for malaria prevention Will support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis WASHINGTON, Feb. 08, 2024 [...]

WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=bJwgaClQttG4SjmXaQa4ZUdGSzouINZVUV7knxw2RAysyNTthtYCgU4ATfeZZRXR-hTVacROoXAlFxit_gWzGsTyD1LofQiNX6JaUEXGqM-J1YsDi-FelubfUHQd4Yby, Inc. (NASDAQ: SXTP; SXTPW) ('60 Degrees Pharmaceuticals' or the 'Company'), specialists in developing and marketing new medicines for the treatment and prevention [...]

WASHINGTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=Up5gNvSoNjd71yV4AU1MtkCXhC-lkKVv6WQYZiDjoCsyjPDCQJNU_Mtksujlr_NYI3gHIYGT7fDyi0ITrCKF7hAByq5XZn6CGCMeda8bFpsz7IEdzxymYkXwDeNwIuaK, Inc. (NASDAQ: SXTP; SXTPW) ('60 Degrees Pharmaceuticals' or the 'Company'), specialists in developing and marketing new medicines for the treatment and prevention [...]

WASHINGTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=fxCOCcGbuIM-1uPpfIBLmxSD3HnIMVGkjCdTMO0NKGhy6SUTLEvvHCbGSzfA69y6FAF1rCns0WXt10nBI7M6gPWTKYUc78zYfNcBHwPayJZb6LSa9OJQh76RJKTefxG2 (NASDAQ: https://www.globenewswire.com/Tracker?data=k3IicwWk7ctAMZ_YJtP3AXmZRWmpTuN33F2M_GZgBpGtF5ChM5SUlZquvRX2eoSr14WlR4k_aGhrD20HOllitCvaCqT5P9koxVf-XarmNgmasqS5vBLjNDBoGzjarUPEPf4aP2MKD1JETETlFnYUUw==; SXTPW) ('60P' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on [...]

Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma's double-blind, placebo-controlled study to investigate tafenoquine for treatment of hospitalized babesiosis patients The previously announced Type C meeting [...]

Type C meeting will be to discuss a proposed Phase II study of tafenoquine for treatment of babesiosis Transmitted by ticks, babesiosis is a life-threatening parasitic disease increasing in frequency [...]

60 Degrees Pharmaceuticals will present scientific poster on new, long-term safety data on the use of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting 60 Degrees Pharmaceuticals [...]

FDA advice to Company suggested execution of ACLR8-LR, a placebo-controlled Phase IIB study of tafenoquine in COVID-19 patients, may not be feasible in the U.S. Company will therefore focus efforts [...]

Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of [...]

60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naive individuals Tafenoquine kills dormant liver [...]

Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035. Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals' USFDA-approved drug for [...]

WASHINGTON, July 14, 2023 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=EiK-hBake5Y4FrYwFaM4JTpIQCx5oUwzEDpcWGVWMAB7fKcK3brgjxu9_GPCuCYkqs4QNSjkfLP6YWa8RxFjm6LSqd6-UNPv6KRKsxHdqpQ6Twae00rOWxXu9hOlr0vn, Inc., (NASDAQ: SXTP; SXTPW) ('60P' or the 'Company'), specialists in developing and marketing medicines for infectious diseases, announced today the closing of [...]

Patent provides exclusive use through 2040 of tafenoquine for treatment of COVID-19 and other lung infections. Tafenoquine is the active molecule in 60P's FDA-approved drug for malaria prevention, ARAKODA[sup. (R) [...]